Helen Torley
CIK: 0001528185
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
HALOZYME THERAPEUTICS, INC.
Discretionary Trading P&L
Holdings
Transaction History (217 total)
- Oct 8, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3.1K shares at avg. $108.91$337K - Oct 8, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Oct 8, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct4.8K shares at avg. $108.18$520K - Oct 8, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct11.9K shares at avg. $110.00$1.3M - Oct 8, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct200 shares at avg. $110.51$22K - Oct 7, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct10.3K shares at avg. $111.84$1.2M - Oct 7, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct900 shares at avg. $112.78$102K - Oct 7, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct200 shares at avg. $113.69$23K - Oct 7, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct8.6K shares at avg. $111.03$955K - Oct 7, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Oct 6, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Oct 6, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct6K shares at avg. $109.33$656K - Oct 6, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct2.3K shares at avg. $107.90$248K - Oct 6, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.8K shares at avg. $110.81$197K - Oct 6, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct9.9K shares at avg. $109.89$1.1M - Sep 11, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct15.5K shares at avg. $107.15$1.7M - Sep 11, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct4.5K shares at avg. $107.55$485K - Sep 11, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Sep 10, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Sep 10, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct14.6K shares at avg. $107.01$1.6M - Sep 10, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct5.4K shares at avg. $107.58$582K - Sep 9, 2026HALO
HALOZYME THERAPEUTICS, INC.
Exercise(M)Direct20K shares at avg. $18.41$368K - Sep 9, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct13.3K shares at avg. $107.22$1.4M - Sep 9, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct6.6K shares at avg. $107.82$711K - Sep 9, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct100 shares at avg. $108.67$11K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 8, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,090 | $108.91 | $336,526 | Direct |
| Oct 8, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Oct 8, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 4,810 | $108.18 | $520,341 | Direct |
| Oct 8, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 11,900 | $110.00 | $1,308,941 | Direct |
| Oct 8, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 200 | $110.51 | $22,102 | Direct |
| Oct 7, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 10,300 | $111.84 | $1,151,942 | Direct |
| Oct 7, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 900 | $112.78 | $101,502 | Direct |
| Oct 7, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 200 | $113.69 | $22,739 | Direct |
| Oct 7, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 8,600 | $111.03 | $954,867 | Direct |
| Oct 7, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Oct 6, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Oct 6, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 6,000 | $109.33 | $656,004 | Direct |
| Oct 6, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 2,300 | $107.90 | $248,175 | Direct |
| Oct 6, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,780 | $110.81 | $197,245 | Direct |
| Oct 6, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 9,920 | $109.89 | $1,090,119 | Direct |
| Sep 11, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 15,492 | $107.15 | $1,660,030 | Direct |
| Sep 11, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 4,508 | $107.55 | $484,826 | Direct |
| Sep 11, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Sep 10, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Sep 10, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 14,588 | $107.01 | $1,561,091 | Direct |
| Sep 10, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 5,412 | $107.58 | $582,228 | Direct |
| Sep 9, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Exercise(M) | 20,000 | $18.41 | $368,200 | Direct |
| Sep 9, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 13,304 | $107.22 | $1,426,481 | Direct |
| Sep 9, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 6,596 | $107.82 | $711,187 | Direct |
| Sep 9, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 100 | $108.67 | $10,867 | Direct |
1-25 of 217 transactions
About Torley Helen
Torley Helen (SEC CIK 0001528185) files insider reports with the SEC as PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC. (HALO).
Signal8 holds 29 ownership filings by Torley Helen, all Form 4s, filed between Sep 12, 2024 and Oct 8, 2026. Those filings report 217 transactions, from Sep 10, 2024 to Oct 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Torley Helen's filings is in SAN DIEGO, CA.
Recent filings by Torley Helen
- Oct 8, 2026: Open-market sale of HALO shares (Form 4, code S).
- Oct 8, 2026: Option exercise of HALO shares (Form 4, code M).
- Oct 8, 2026: Open-market sales of HALO shares (3 lines, Form 4, code S).
- Oct 7, 2026: Open-market sales of HALO shares (4 lines, Form 4, code S).
- Oct 7, 2026: Option exercise of HALO shares (Form 4, code M).
Other insiders filing for HALOZYME THERAPEUTICS, INC. (HALO)
- Connaughton Bernadette, Director
- Daly James M, Director
- Posard Matthew L., Director
- Appelhans Dannielle, Director
- RAMSAY DAVID A, EVP, PRESIDENT, DRUG DELIVERY
- Snellgrove Darren, SVP, Chief Financial Officer